OasisLMS

Thymomas are rare malignant tumors, making large prospective trials difficult and resulting in treatment guidelines that rely heavily on expert opinion rather than high-level evidence. Because most clinicians encounter few cases, patients are often referred to specialized centers where management decisions are made through multidisciplinary tumor boards, particularly for complex stage III and IVa disease. This microlearning synthesizes available retrospective data and expert consensus to highlight practical, evidence-informed approaches to managing advanced thymoma.

This activity is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer including medical oncologists, thoracic surgeons, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician associates.

Upon succesful completion of the activity, learners should be able to:

• Be comfortable presenting a patient with stage III thymoma in a multidisciplinary tumor board
• Determine the optimal treatment regiment for Stage III thymoma
• Discuss future areas of study in the management of Stage III thymoma

Case Summary | Jefferey Velotta, MD, FACS, Assistant Professor, Kaiser Permanente, United States
Radiology Perspective | Ioannis Vlahos, MD, Professor, MD Anderson Cancer Center, United States
Pathology Perspective | Anja C. Roden, MD, Professor, Mayo Clinic, United States
Thoracic Surgery Perspective |  Jefferey Velotta, MD, FACS, Assistant Professor, Kaiser Permanente, United States
Medical Oncology Perspective | Fatemeh Ardeshir-Larijani, MD, MSc, Assistant Professor, Emory University, United States

If you need assistance with this activity, please email: education@iaslc.org.